SOPHiA GENETICS reported preliminary Q4 2025 revenue of $21 million, a 20% year‑over‑year increase from $17.7 million in Q4 2024. Full‑year 2025 revenue reached $77 million, up 18% from $65.2 million in 2024, driven by a record 391,000 analyses on its SOPHiA DDM platform and strong uptake of its MSK‑ACCESS liquid‑biopsy application.
The company’s growth was underpinned by a surge in U.S. demand, with new customer signings across the oncology and diagnostics markets. A renewed multi‑year partnership with AstraZeneca for AI‑driven breast‑cancer analytics added a significant revenue stream, while the MSK‑ACCESS platform continued to capture market share in liquid‑biopsy testing.
Gross‑margin expansion to 74.4% in Q2 2025 reflected operational efficiencies and a higher mix of high‑margin platform contracts. The company’s cost structure remained disciplined, allowing it to maintain margin growth even as it invested heavily in platform scale and new product development.
For 2026, SOPHiA GENETICS guided revenue of $92–$94 million, representing 20–22% year‑over‑year growth. The company projected an adjusted EBITDA loss of $29–$32 million, with no explicit reaffirmation of a breakeven target by late 2026 in this announcement.
The leadership transition will see Ross Muken, the current president, assume the CEO role effective July 1 2026, while co‑founder Jurgi Camblong will become Executive Chairman. The change follows a long‑term succession plan designed to accelerate growth under new executive leadership.
Jurgi Camblong said, “2025 was a tremendous year for SOPHiA GENETICS as we reaccelerated revenue growth and materially exceeded our new‑business bookings target, setting the stage for robust future growth. Our strong performance in 2025 positions us well for continued growth in 2026 and beyond.”
The results and guidance signal a company that is scaling its AI‑powered platform while maintaining disciplined cost control. The 18% revenue growth, record analysis volume, and margin expansion demonstrate operational leverage, while the 2026 guidance reflects confidence in sustained demand and a clear path toward profitability as the company continues to invest in high‑return verticals.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.